Phase II Study of Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers
Summary
The purpose of this phase II study is to test the safety of giving MVT-5873 at surgery to remove cancer and see if it slows the progression of the disease.
General Information
NCT#: NCT03801915
Study ID: 190039
Trial Phase: Phase II
Trial Sponsor: National Cancer Institute (NCI)
Therapies Used in This Trial: MVT-5873